Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Georgia-Myrto Prifti"'
Autor:
Dimitrios Moianos, Maria Makri, Georgia-Myrto Prifti, Aristeidis Chiotellis, Alexandros Pappas, Molly E. Woodson, Razia Tajwar, John E. Tavis, Grigoris Zoidis
Publikováno v:
Molecules, Vol 29, Iss 12, p 2942 (2024)
Hepatitis B virus (HBV) remains a global health threat. Ribonuclease H (RNase H), part of the virus polymerase protein, cleaves the pgRNA template during viral genome replication. Inhibition of RNase H activity prevents (+) DNA strand synthesis and r
Externí odkaz:
https://doaj.org/article/92d2fc12da214c62bb8eb197a88cae60
Publikováno v:
Pharmaceuticals, Vol 16, Iss 6, p 901 (2023)
Metalloenzymes are central to the regulation of a wide range of essential viral and parasitic functions, including protein degradation, nucleic acid modification, and many others. Given the impact of infectious diseases on human health, inhibiting me
Externí odkaz:
https://doaj.org/article/a8243f3f6ec14f17aff0f38ee27bd3f1
Autor:
Georgia-Myrto Prifti, Dimitrios Moianos, Erofili Giannakopoulou, Vasiliki Pardali, John E. Tavis, Grigoris Zoidis
Publikováno v:
Pharmaceuticals, Vol 14, Iss 5, p 417 (2021)
Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos(t)ide analogues, h
Externí odkaz:
https://doaj.org/article/82478afa5f3746a0a81484546b91e960
Autor:
Dimitrios Moianos, Georgia-Myrto Prifti, Vasiliki Pardali, Grigoris Zoidis, John E. Tavis, Erofili Giannakopoulou
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 417, p 417 (2021)
Pharmaceuticals, Vol 14, Iss 417, p 417 (2021)
Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos(t)ide analogues, h